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ABSTRACT
Objective: As their proportion rises in the aging population, cardiovascular disease and osteoporosis increasingly become significant health problems 
of the developed world, leading to reduced lifespan and substantial financial burdens, not the least because of complications and comorbidities 
associated with each disorder. This study investigates bone mineralization in patients with coronary heart disease (CHD) complicated by Stage I 
chronic heart failure (CHF).
Methods: The study group consisted of 41 patients of both sexes with CHF Stage I against the background of CHD that with no severe comorbidities 
that could have potentially caused changes in bone tissue. Bone mineral density was measured using dual-energy X-ray densitometry of lumbar region 
of spine and proximal right femur.
Results: Structural and functional changes in the bone of the lumbar spine were found in 75.9% of the patients with Stage I CHF caused by CHD. 
Osteopenia was diagnosed in 64.4% of the patients, while osteosclerotic bone changes were less frequent and found in 11.5% of the patients. 75.8% 
of the patients had structural and functional changes in the proximal segment of the right femur bone. In men with Stage I CHF against the background 
of CHD osteopenia was more often diagnosed in the proximal segment of the right femur, while in women it was found in almost equal proportion in 
the spine and hip.
Conclusions: In both sexes with I Stage CHF against the background of CHD were diagnosed changes in bone mineralization, with osteopenia being 
the prevailing diagnosis.
Keywords: Coronary disease, Osteopathy, Bone density.
INTRODUCTION
Although structural changes of the spine are primarily connected with 
aging, so-called diseases of civilization, which predominately include 
cardiovascular system disorders, increase the pace of osteopathic 
changes [1]. The prevalence of cardiovascular diseases (CVD) is a global 
health problem that leads to impaired quality of life and shortens life 
expectancy [2]. CVD are the most frequent cause of morbidity and 
mortality not only in developed nations but also in developing nations [3]. 
CVD, as well as osteoporosis, are high-burden health issues due to their 
increased incidence with age and significant monetary costs needed for 
treatment of such patients [4]. Chronic heart failure (CHF) is a syndrome 
rather than a disease, the cause of which may be structural or functional, 
or more often than not, both. Whatever be the underlying cause, the 
cardinal symptoms are dyspnea and fatigue leading to a progressive 
decrease in exercise capacity [5]. It should be noted that CHF and 
osteoporosis are often diagnosed in the same patient [6]. The majority 
of the studies have shown that individuals with CVD have a higher risk 
of experiencing bone loss and thus greater predisposition to the risk of 
fracture. On the other hand, there is growing evidence that individuals 
with low bone mass have a higher mortality for cardiovascular events 
compared to patients with CVD with normal bone mass [7]. Recent 
recommendations suggest that elderly patients with low bone mineral 
density (BMD) require thorough evaluation for possible CVD [8]. 
Likewise, another study recommends taking into account the possibility 
of CVD in elderly patients being treated for osteoporosis [9]. Since the 
treatment of osteoporosis and its complications is a difficult, time-
consuming and not always effective process, currently the predominant 
approach in dealing with this disease is prevention.
Objectives
This study aims to investigate bone mineralization in patients with 
coronary heart disease (CHD) complicated by Stage I CHF.
METHODS
The study involved 41 patients of both sexes aged from 40 to 70 years 
with Stage I CHF (according to the classification by Strazhesko, Vasilenko 
and Lung [1935]) against the background of coronary artery disease. 
The patients did not have other severe comorbidities that could have 
caused changes in bone tissue. All study participants were hospitalized 
patients and had given written consent for their clinical data to be used 
in the study. All reported research conducted in accordance with the 
principles set forth in the Helsinki Declaration, 2008.
Diagnosis of coronary artery disease was confirmed using a set 
of characteristic anamnestic, clinical (typical angina attacks with 
physical and psycho-emotional stress), biochemical (increased total 
cholesterol and total lipids levels), and electrocardiography (ST-
segment depression below the baseline and T-wave inversion) data. 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i1.17532
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To corroborate diagnosis, we also used data obtained during a physical 
examination, such as enlarged to the left heart boundaries, weakened 
sound of the top tone, stress of the second tone above the aorta, and 
changes in blood pressure and heart rate.
To verify the diagnosis of heart failure, we used main limiting factors 
of physical performance and clinical symptoms: Dyspnea, tachycardia, 
and fatigue after exertion. The final diagnosis of CHF with systolic 
dysfunction was given based on the results of echocardiography test.
Among the patients included in the study, 23 (56.1%) were men and 18 
(43.9%) women. The average age of men was 56.05±1.68 years. While 
their body mass index (BMI) exceeded normal range (set at <25 kg/m2) 
and was in the range of uncompensated obesity, 28.25±0.80 kg/m2, it 
was not significantly different from BMI of research groups. The average 
age of women was 58.11±2.09 years, their BMI also exceeded that of 
the control group by 16% and was in the range of uncompensated 
obesity, 28.08±1.20 kg/m2. Clinical characteristics of the patients in 
the experimental group were as follows: The disease duration ranged 
from 2 to 5 years, the underlying disorders mainly were postmyocardial 
infarction cardiosclerosis and stable angina.
During the initial assessment, we found no significant statistical 
differences anthropometric characteristics such as age, BMI, and 
length of the between male and female patients, thus for the purposes 
of subsequent statistical analysis, we directly compared these 
two groups.
DXA is widely used for measuring BMD because of its recognized precision 
[10]. The method utilizes two measurements, T-score and Z-score. The 
first one is calculated when the patient’s BMD is subtracted from mean 
BMD of a population of healthy young adults, matched. The T-score is 
calculated as a number of SDs the patient’s measured BMD is above or 
below the mean for the population of healthy 30-year adults, matched for 
sex and ethnicity. The Z-score is expressed in units of the population SD, 
but instead of comparing the patient’s BMD to the mean of the young adult 
population, it is compared with the mean BMD of a healthy population 
matched for age, sex, and ethnicity. In this study, we evaluated the scores 
according to the WHO guidelines (WHO, Geneva, 1994): BMD >1.2 g/sm2 
is classified as osteosclerosis; a T-score ≥ −1 is regarded as normal and 
T-score between −2.5 and −1 is classified as osteopenia [11].
The control population samples were selected from a densitometric 
database of healthy individuals maintained at the medical diagnostic 
center of Ternopil State Medical University and designated as young 
adults and age-matched groups [12,13].
The results were analyzed using Statistica 7.0 software and presented 
as mean with standard deviations. To evaluate the distribution of 
the character together by sampling data, we have used Lilliefors and 
Kolmogorov - Smirnov tests. The differences between all groups were 
determined using one-way ANOVA, followed by post hoc least significant 
difference test. p<0.05 was considered statistically significant.
RESULTS
Densitometry analysis of lumbar segment in the second group of 
patients with Stage I CHF showed that in men normal BMD was 
Table 2: BMD of the lumbar spine in patients with CHF Stage I and its departure from bone mass density of healthy young adults 
(young adult) group
BMD state Vertebra number Young adult
% Departure Т-score





L1 95.50±2.55 85.75±1.79* −0.41±0.25 −1.35±0,16*
L2 94.14±1.26 86.13±1.67* −0.6±0.14 −1.39±0,17*
L3 92.14±2.91 90.75±1.48 −0.83±0.30 −0.93±0.15




L1 96.75±1.52 100.00± 0.00 −0.33±0.15 0.00±0.00
L2 100.00±1.74 92.00± 0.00 0.00±0.19 −0.80 ±0.00
L3 99.63±1.55 97.00±0.00 −0.04±0.16 −0.3±0.00




L1 101.17±2.72 115.00±5.04 0.10±0.26 1.47±1.42
L2 106.17±2.15 114.67±8.01 0.65±0.23 1.47±0.80
L3 111.00±2.17 121.33±10.11 1.12±0.23 2.13±1.01
L4 108.00±2.35* 120.00±4.36 0.80±0.25* 2.00±0.44
*Indicates significance of difference in values for male and female groups (p<0.05), BMD: Bone mineral density, CHF: Chronic heart failure
Table 1: BMD of the lumbar spine in patients with CHF Stage I








L1 1.10±0.03 0.93±0.02 <0.001
L2 1.16±0.02 1.01±0.02 <0.001
L3 1.14±0.04 1.07±0.02 >0.05




L1 1.14±0.02 1.13±0.00 –
L2 1.24±0.02 1.10±0.00 –
L3 1.23±0.02 1.17±0.00 –




L1 1.17±0.03 1.30±0.17 >0.05
L2 1.31±0.03 1.38±0.10 >0.05
L3 1.37±0.02 1.45±0.12 >0.05
L4 1.33±0.03 1.44±0.05 >0.05
p-value indicates significant difference between the sexes, BMD: Bone mineral 
density, CHF: Chronic heart failure
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predominate (43.5%), while osteopenia and osteosclerotic bone 
changes were diagnosed with almost equal frequency. In women, 77.8% 
had osteopenia and 22.2% osteosclerotic bone changes (Tables 1-3). 
It should be noted that in females diagnosed with osteopenia the 
indicators of BMD were significantly lower than in men at L1 and L2, 
whereas in patients with increased mineralization BMD changed in the 
same way in both sexes in all studied vertebrae (Table 1).
A comparative analysis of indicators of the detected peak BMD to that 
in young healthy subjects in Table 2 shows that compared with men, 
in women with osteopenia the mineral content reduction in the first 
two lumbar vertebrae is more pronounced, while BMD is significantly 
increased in cases of osteosclerosis at L4. Because we found no CHF 
Stage I female patients with preserved BMD, it was not possible to 
compare male and female BMD indicators in this group.
Age-matched BMD measurements (% departure and Z-score) in men 
diagnosed with osteopenia do not differ from their BMD scores relative 
to young healthy adults (p>0.05), while in women scores calculated 
in relation to the age-matched were higher than the ones to young 
adult: At L1 by 1.67 times; L2 by 1.96 times; L3 by 1.46 times; and L4 
by 1.68 times.
BMD data of the right proximal femur (Table 4) show a large number of 
osteopenia cases (61.8%) compared to those of preserved BMD (38.2%), 
indicating more pronounced changes of thigh bone tissue as opposed to 
the lumbar spine. Densitograms of the patients with low mineralization 
show in 100% of the cases osteopenia in Ward’s triangle (Δ), in 30.77% 
of the cases osteopenia of the femoral neck, and in 7.69% of the cases 
general osteopenia. In men, we diagnosed no bone changes in the 
greater trochanter. Assessing the osteopenic syndrome, we found 
significantly lower (p<0.05) rates of BMD relative to the young adult 
group (% departure and T-score) in all surveyed areas compared with 
normal bone tissue in male patients with CHF Stage I. The indicators 
of bone tissue mineralization of the same patients relative to the age-
matched group (% departure and Z-score) were also lower (p<0.05) in 
the femoral neck, Δ Ward section and the proximal femur.
Comparative analysis of the structural and functional condition of the 
hip bone in female patients with CHF Stage I show the prevalence of 
bone demineralization. Various degrees of osteopenia were found 
in 61% of the patients, while 39% exhibited preserved BMD. When 
compared to the young adult reference group, right femur BMD values 
in these women show bone density decrease in the femoral neck, Ward’s 
triangle and the greater trochanter as measured by both % departure 
and T-score. At the same time, the ratio of the female patients’ BMD to 
that of the age-matched group was significantly higher than the ratio of 
the patients’ BMD to the young adult group (Table 5).
Given the large number of patients with CHF Stage I diagnosed with 
osteoporosis of proximal femur, we analyzed the extent of osteopenia. 
Among the 24 patients, Stage 1 osteoporosis was diagnosed: In the neck, 
Table 3: BMD of the lumbar spine in patients with CHF Stage I and its departure from bone mass density of age-matched group
BMD state Vertebra number Age-matched
% Deviation Z-score






L1 94.86±2.05 91.07±2.62 −0.50±0.20 −0.81±0.24
L2 93.29±2.59 92.50±2.04 −0.70±0.27 −0.71±0.20
L3 91.29±3.57 98.36±2.88 −0.90±0.37 −0.20±0.26




L1 101.40±1.36* 121.00±0.00 0.12±0.13* 1.60±0.00
L2 102.70±1.96* 110.00±0.00 0.26±0.20* 0.80±0.00
L3 102.10±2.00* 117.00±0.00 0.20±0.20* 1.40±0.00




L1 100.50±4.00* 123.33±12.41 -0.02±0.38* 1.87±1.36
L2 105.17±2.36* 123.00±5.57 0.53±0.24* 2.13±0.58
L3 109.83±2.75* 130.00±7.21 1.00±0.27* 2.80±0.74
L4 106.83±1.97* 128.67±2.33 0.73±0.20* 2.70±0.23
*Indicates significance of difference in values for male and female groups (p<0.05), BMD: Bone mineral density, CHF: Chronic heart failure
Table 4: BMD of the proximal right femur in male patients with CHF Stage I
BMD state Area of femur BMD, g/sm2 Young adult Age-matched
% Departure T-score % Departure Z-score
Osteopenia syndrome (n=13) Neck 0.95±0.02* 91.38±1.26 −0.73±0.10 97.54±1.63* −0.20±0.13*
Ward’s triangle 0.76±0.02* 68.50±0.49* −1.61±0.12* 92.85±2.24* −0.48±0.14*
Troch 0.92±0.02* 98.00±1.40* −0.14±0.12* 101.46±2.30* 0.12±0.19*
Total 1.03±0.01* 95.63±0.63* −0.34±0.05* 100.15±1.59* −0.01±0.12*
Preserved (n=8) Neck 1.05±0.01 100.37±5.40 0.05±0.44 107.12±3.55 0.55±0.28
Wards 0,98±0.07 102.34±6.81 0.03±0.37 117.37±5.63 1.09±0.35
Troch 1.02±0.03 114.50±5.39 1.05±0.28 114.32±3.61 1.11±0.24
Total 1.16±0.04 103.86±5.28 0.77±0.40 113.00±2.94 0.95±0.23
*Indicates significant difference between patients with normal and reduced BMD (p<0.05), BMD: Bone mineral density, CHF: Chronic heart failure
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Table 5: BMD of the proximal right femur in female patients with CHF Stage I
BMD state Area of femur BMD, г/см2 Young adult Age-matched
% T % Z
Osteopenia syndrome (n=13) Neck 0.89±0.02* 90.38±1.65* −0.80±0.13* 100.45±2.18* 0.03±0.16*
Ward’s triangle 0.72±0.02* 80.63±1.51* −1.36±0.10* 96.18±3.83* −0.25±0.22*
Troch 0.76±0.03* 97.63±3.20* −0.15±0.23* 100.30±3.24* 0.01±0.22*
Total 0.95±0.03 96.00±2.31* −0.34±0.18 102.45±3.05* 0.16±0.21*
Preserved (n=8) Neck 1.09±0.10 112.25±9.46 1.00±0.78 121.25±7.44 1.59±0.66
Wards 0.95±0.08 103.50±8.15 0.29±0.57 123.95±7.97 1.36±0.51
Troch 0.97±0.10 118.54±9.77 1.60±0.82 121.96±7.65 1.54±0.58
Total 1.11±0.08 109.50±5.65 0.55±0.50 116.87±4.65 1.21±0.35
*Indicates significant difference between patients with normal and reduced BMD (p<0.05), BMD: Bone mineral density, CHF: Chronic heart failure
in 5 individuals; Δ Ward, 12; the greater trochanter, 2; and throughout 
the proximal femur, in 3. Stage 2 osteoporosis was diagnosed in the 
neck of femur of 2 patients and Δ Ward of 6; while Stage 3 osteoporosis 
was diagnosed in Δ Ward noted of 4 patients. Patients with primary 
osteopenia had BMD in the femoral neck (0.88±0.02) g/sm2, in Δ Ward 
- (0.78±0.01) g/sm2, in the trochanter area (0.66±0.01) g/sm2, and 
overall (0.88±0.03) g/sm2.
Comparison of T-scores showed that the most significant BMD 
changes were observed in Δ Ward (−1.29±0.04), followed by the neck 
(−1.24±0.05), greater trochanter (−1.20±0.00), and in the total proximal 
area of the femur (−1.17±0.07). In Stage 2 osteoporosis, BMD of Δ Ward 
(0.71±0.01) g/cm2 was significantly lower than the same indicator in 
the neck of the femur (0.82±0.04) g/cm2.
Decrease in bone mineralization was reflected in decreased T-score, 
which in the area of Δ Ward was 10.6% lower than in the neck of the 
femur. Stage 3 osteoporosis was diagnosed in 4 patients; their BMD 
was (0.65±0.02) g/sm2, and the T-score was (−2.28±0.09). The results 
indicate that in men with CHF Stage I osteopenia syndrome is more 
often diagnosed in the proximal right femur, while in women it is 
diagnosed almost equally often in the spine and hip.
DISCUSSION
Studies point to the connection of CVD with decreased BMD [14,15]. 
CVD and osteoporosis are major causes of morbidity, mortality, and 
disability.
Myocardium’s ability to contract is an important factor determining 
adequate blood circulation in organs and tissues. Isotropic function of 
the heart depends on the interaction of cytosol calcium with contractile 
proteins. Increased interaction may be due to increasing calcium levels 
in cardiomyocytes during the systole or increased sensitivity of the 
protein structures to calcium [16]. In this study, we aimed to show the 
relationship of CHF with pathological changes in bone tissue that are 
generally not caused by the usual risk factors.
There are well-characterized biochemical changes observed during 
CHF, including reduced activity of enzymes that regulate calcium 
homeostasis; inhibited calcium ATPase in the sarcoplasmic reticulum; 
and increased activity of sarcolemmal sodium-calcium exchange [17]. 
These changes are accompanied by shifts in calcium homeostasis, with 
decreased diastolic capture of calcium in the sarcoplasmic reticulum, 
followed by decrease in calcium release during the next systole, 
resulting in hypercontractivity of the myocardium. Results of this study 
suggest that during CHF advance the levels of calcium and phosphorus 
in the blood may be supported at the expense of the destruction of 
the bone tissue, which, in some cases, can initiate development of 
osteoporosis. Therefore, we believe that CVD is one of the factors that 
reduce BMD, while bone demineralization, in turn, complicates the 
course of CHF pathology.
As a result, structural and functional changes in the bone tissue of the 
lumbar spine were found in 75.9% of patients with Stage 1 of CHF 
caused by ischemic heart disease: 64.4% of patients had osteopenic 
syndrome, and the rest, 11.5%, osteosclerotic changes. In 75.8% of 
CHF patients, we found structural and functional changes in the bone 
tissue of proximal right femur. In men with CHF Stage I against the 
background of CHD, osteopenic syndrome was more often diagnosed 
in the proximal right femur, while in women in almost equal measure 
in the spine and hip.
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